- BNF:
- 2.5.5.2
- Status:
- Grey
- Decision Date:
- August 2012
Comments
Formulary ARBs are the most cost-effective options.
Grey Drug Classifications
- 1: Lack of data on effectiveness compared with standard therapy
- 2: Lack of data on safety compared with standard therapy
- 5: Less cost-effective than current standard therapy
search again